Post-approval studies (Phase 4)Study completedNCT02485691
What this trial is testing
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Who this might be right for
Prostate Cancer Metastatic
Sanofi 255